What type of study is this?

October 9, 2025Gut

Galectin-4 drives anti-PD-L1/BVZ resistance by regulating metabolic adaptation and tumour-associated neutrophils in hepatocellular carcinoma

View Full Paper

Ask AI

Bookmark

Resistance to ATZ/BVZ therapy in HCC was linked to elevated galectin-4 levels, indicating its role in poor prognosis.
Galectin-4 overexpression diminished the effects of ATZ/BVZ by promoting metabolic adaptation and a suppressive tumor microenvironment.
Single-cell RNA sequencing and preclinical models demonstrated essential mechanistic roles of galectin-4 in metabolic and immune responses.
Targeting galectin-4 reversed resistance, supporting its potential as a therapeutic target in HCC treatment.

No takes yet. Share an insight, caveat, or question.

Observational analysis reveals galectin-4 impacts resistance in HCC to ATZ/BVZ therapy, suggesting potential targets for improving treatment.

Xu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis reveals galectin-4 impacts resistance in HCC to ATZ/BVZ therapy, suggesting potential targets for improving treatment.